elironrasib
AXP000028.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Revolution Medicines
- Sponsor
- Revolution Medicines
Names
Cross-references
- NCI Thesaurus
- C189824
- Wikidata
- Q140529143
- FDA UNII
- 942KVV5CJP
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Recruiting | Phase 1/2 | 2026-01-30 | 2029-05 | 370 | Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC) |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Recruiting | Phase 1/2 | 2024-01-18 | 2027-06 | 616 | KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Recruiting | Phase 1/2 | 2023-11-14 | 2028-12 | 534 | Colorectal Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Active not recruiting | Phase 1 | 2022-09-19 | 2027-03-31 | 222 | Advanced Solid Tumor; Colorectal Cancer (CRC); Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40056080 | Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. | Journal of medicinal chemistry | 2025 | cited by trial NCT06128551 |
| PMID 37590355 | Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. | Science (New York, N.Y.) | 2023 | cited by trial NCT05462717 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41165456 | RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. | Cancer research | 2026 | name in abstract: elironrasib |
| PMID 41340466 | Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Molecular cancer therapeutics | 2026 | name in abstract: RMC-6291 |
| PMID 41405236 | "The RAS Dam Has Broken". | Cancer discovery | 2026 | name in abstract: elironrasib |
| PMID 41670434 | Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. | Cancer discovery | 2026 | name in abstract: elironrasib |
| PMID 42457978 | Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators. | Acta pharmacologica Sinica | 2026 | name in abstract: RMC-6291 |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: RMC-6291 |
| PMID 42841489 | Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: elironrasib |
| PMID 42870846 | Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines. | Translational lung cancer research | 2026 | name in abstract: elironrasib |
| PMID 42963543 | KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. | Journal of hematology & oncology | 2026 | name in abstract: elironrasib |
| PMID 42975930 | Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in abstract: elironrasib |
| PMID 42984346 | Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: elironrasib |
| PMID 39993169 | Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers. | Journal of medicinal chemistry | 2025 | name in title: elironrasib |
| PMID 39215000 | RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. | Nature communications | 2024 | name in abstract: RMC-6291 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC011892 | Targeting RAS in Pediatric Cancer | DIVISION OF BASIC SCIENCES - NCI | YOHE, MARIELLE | 2019–2025 | name in abstract: RMC-6291 |
Notes
KRAS G12C(ON) covalent tri-complex inhibitor. Wikidata QID not confirmed.
How to cite
elironrasib (AXP000028.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000028.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.